Pharmaceutical laboratories rely on validated analytical methods, controlled workflows, and defensible data. LC-MS, GC-MS, HPLC, dissolution testing, spectroscopy, and other established techniques remain central to release testing, stability studies, impurity analysis, and regulated quality control.
DART-MS fits a different role. Direct analysis in real time mass spectrometry can help laboratories screen samples faster when the goal is early information rather than final release data. It can analyze solid pharmaceuticals, tablets, powders, extracts, and surfaces with limited preparation, giving scientists a rapid view of chemical composition before deeper testing begins.
That speed can support screening, troubleshooting, and investigation. It should not be treated as a shortcut around validation.
Why Pharmaceutical Labs Consider DART-MS
Many pharmaceutical questions start before a full validated method is needed. A lab may need to check whether a tablet contains the expected active ingredient, investigate a suspicious product, compare raw material lots, or explore an unexpected signal during development.
DART-MS can help answer those early questions fast. A study of solid pharmaceutical samples showed how DART-MS can rapidly screen for active ingredients with limited sample preparation. That type of application shows why the technique attracts interest: it can reduce preparation time and give analysts a quick chemical readout.
Working in analytical science?
Register for a FREE Separation Science account to subscribe to the Separation Science Newsletter.
For pharmaceutical laboratories, the strongest use cases tend to sit at the front end of a workflow. DART-MS can help scientists decide which samples need confirmatory testing, targeted LC-MS, or a more detailed investigation.
Counterfeit and Falsified Medicines
Counterfeit and falsified medicines create analytical challenges because products may contain the wrong active ingredient, too little active ingredient, undeclared compounds, or harmful substitutes. Screening tools need to work across tablets, capsules, powders, and other product forms.
DART-MS can support this work by giving analysts a fast way to check chemical profiles. A counterfeit tablet study reported DART-MS as an approach for detecting counterfeit drugs in tablets. More recent work has also explored DART-based screening in suspect counterfeit tablets. An FDA Science Forum poster described rapid screening of nitazene analogs in suspect counterfeit tablets using Raman, SERS, FT-IR, and DART-TD-MS.
These examples highlight a practical role for DART-MS. It can help flag suspicious products and guide follow-up testing. Final conclusions still need methods that fit the regulatory, legal, or safety context.
Raw Materials, Excipients, and Troubleshooting
DART-MS may also support screening of raw materials, excipients, and formulation components. In development or investigational settings, scientists may need to compare lots, check for unexpected compounds, or investigate surface residues on materials and equipment.
The technique can help because it reduces the barrier to first-pass analysis. Instead of building a full chromatographic method for every early question, scientists can use DART-MS to gather rapid chemical information and decide whether a deeper workflow is justified.
That can help in several scenarios:
- Raw material checks: Comparing chemical profiles across suppliers or lots.
- Excipient screening: Looking for unexpected components or formulation differences.
- Surface investigations: Screening residues on tools, packaging, or contact materials.
- Development troubleshooting: Investigating unexpected peaks, discoloration, or sample changes.
- Counterfeit screening: Flagging products that differ from expected chemical profiles.
These uses require clear limits. DART-MS can support investigation, but it does not replace validated identity, purity, or potency testing.
Biopharma and Complex Molecules
Biopharmaceutical workflows create a tougher fit for DART-MS. Proteins, oligonucleotides, glycans, and other large or labile molecules often require carefully controlled sample preparation, separation, and ionization. LC-MS remains central for many characterization and impurity workflows because it provides separation, sensitivity, and method control.
DART-MS may still have selective value in biopharma-adjacent workflows. It could support screening of small-molecule impurities, excipients, formulation components, cleaning residues, packaging-related compounds, or process-related chemicals. It may also help during early troubleshooting when scientists need a fast chemical snapshot rather than full molecular characterization.
The key is to match the method to the question. DART-MS suits rapid chemical screening better than detailed characterization of complex biologics.
What DART-MS Cannot Replace
Pharmaceutical analysis demands high confidence. A rapid screen may help analysts act faster, but regulated decisions require validated methods with defined performance.
Key constraints include:
- Limited separation: Co-occurring compounds can complicate interpretation.
- Matrix effects: Formulation components may change signal response.
- Quantitation limits: Screening data may not support potency or impurity reporting.
- Complex molecule limits: Large biomolecules may require specialized LC-MS workflows.
- Regulatory expectations: Release testing and formal QC need validated, documented methods.
These constraints make DART-MS a targeted tool rather than a universal solution. Its value depends on a clear screening purpose and a defined confirmation pathway.
A Practical Screening Role
DART-MS can help pharmaceutical laboratories move faster at the investigative stage. It can screen solid products, flag suspect medicines, compare materials, and guide deeper analytical work.
The technique works best when laboratories define the decision it supports. Is the goal to flag a counterfeit product? Compare raw material lots? Investigate a surface residue? Decide whether a sample needs LC-MS confirmation?
When that purpose is clearly defined, DART-MS can add speed without weakening scientific rigor. It gives pharmaceutical scientists a faster route to the next analytical step, while established methods continue to provide the confidence required for final decisions.
